A Phase 4 interventional study of acetated Ringers and albumin 5% in Colorectal Cancer, Urologic Cancer and Gynecologic Cancer, sponsored by Joachim Zdolsek. Completed at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Joachim Zdolsek · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.
Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 68th largest by enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2023, is one of 3 in phase 4, and was the 99th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Region Skane · Sites in Sweden
Ages 18+
GE Healthcare · Sites in Sweden, United States
Ages 18+
Suturion AB · Sites in Sweden
Ages 18+
Umeå University · Sites in Sweden
Ages 18+
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 28 · Phase 3 34 · Phase 4 3
First in 1998; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 215 across the 89 interventional studies, 242 across the 33 observational. Of the 73 that completed or were terminated, 19 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 124 have an industry lead sponsor. The 10 most frequent:
Joachim Zdolsek is the lead sponsor of 2 studies on the registry; none are open to participants now.
Joachim Zdolsek has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Colorectal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT06333392Vestre Viken Hospital TrustTotal Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | 2026-12 |
| NCT05755672Region SkaneOn-treatment Biomarkers in Metastatic Colorectal Cancer for Life | 2026-12 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 124 studies in Colorectal Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.
60 patients scheduled for laparoscopic abdominal surgery, with a duration exceeding 90 minutes will be included in the study. These are randomized to three different groups (20 in each groups): The first group of patients will receive boluses of acetated Ringers 4 ml/kg body weight. The second albumin 4 ml/kg body weight and the third group albumin 20% 1 ml/kg body weight.
Hemoglobin, albumin and colloid osmotic pressure (COP) is sampled the day before surgery and in the morning directly prior to the anesthesia. Bioimpedance, urine osmolality and urine-creatinin are also measured. After induction of surgery a Cardio Q probe is inserted threw the nose into the esophagus, for circulatory measurements. Initial/baseline blood samples are taken after insufflation of carbon dioxide to the abdomen. Before every bolus of fluid and 5, (10), 15, 20, 30, 40, (50) and (60) minutes new blood samples are taken for determination of hemoglobin, albumin and COP. Artery blood gases are sampled 15 minutes after every infusion or depending on the clinical need.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
Drug: acetated Ringers
The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied.
Drug: albumin 5%
The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
Drug: albumin 20%
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
Also known as: Ringer's acetate, ringer acetate, acetate Ringer´s
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Also known as: Albumin (Human) 5%, Human Albumin 5%
After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Also known as: Human Albumin 20%, Albumin (Human) 20%
Plasma volume expansion after a fluid bolus
Plasma volume using hemoglobin as an indicator of dilution
Time frame: 60 minutes after an intravenous fluid bolus
Fluid Balance
Calculations of fluid balance
Time frame: 18 to 24 hours
Stroke Volume
Change in stroke volume, measured with Cardio Q (oesophageal Doppler monitoring (ODM))
Time frame: 60 minutes after an intravenous fluid bolus
Arterial Blood Pressure
Mean Arterial Pressure, measured with an arterial line.
Time frame: 60 minutes after an intravenous fluid bolus
Heart Rate
Heart rate, measured with ECG and pulseoximeter.
Time frame: 60 minutes after an intravenous fluid bolus
Bioimpedance
Bioimpedance measures, resistance and impedance converted to volume of body fluid compartments.
Time frame: 18 to 24 hours
Serum Creatinin
Serum Creatinin as a measure of kidney function
Time frame: 18 to 24 hours
arterial pH
Influence of a fluid bolus on arterial blood gases
Time frame: 60 minutes after an intravenous fluid bolus
arterial Base Excess
Influence of a fluid bolus on arterial blood gases
Time frame: 60 minutes after an intravenous fluid bolus
arterial serum sodium
Influence of a fluid bolus on Sodium concentration
Time frame: 60 minutes after an intravenous fluid bolus
arterial serum chloride
Influence of a fluid bolus on Chloride concentrations
Time frame: 60 minutes after an intravenous fluid bolus
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual de-identified results will be shared, when results are published.
Ran from Oct 2023 to primary completion in Jun 2026, 31 months.
Of 38 phase 4 interventional studies under Colorectal Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 57. This study's 31 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Jun 2026 and completion Oct 2026 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ringer's acetate · Albumins
Joachim Zdolsek